Endurance announced that its commercial partner Wanbang Biopharmaceuticals has completed a Phase III study of Fortacin (lidocaine/prilocaine) in China for the treatment of premature ejaculation (PE).

The 295-patient, placebo-controlled Phase III trial met all four co-primary endpoints. Fortacin has marketing authorisation for PE in the EU, and Senstend is the brand name for Fortacin in China.

Intravaginal ejaculation latency time (IELT), index of premature ejaculation (IPE) ejaculatory control, and IPE sexual satisfaction domains, as well as IPE distress, all showed positive results compared to baseline and placebo. Fortacin increased IELT, ejaculatory control and satisfaction while reducing distress.

Fortacin is a formulation of metered dose aerosol of lidocaine and prilocaine. It provides topical anaesthesia to the glans penis with lidocaine and prilocaine blocking the transmission of nerve impulses resulting in sensitivity reduction.

Premature ejaculation is a common occurrence in men. There are two types: primary, a long-term occurrence; and secondary, where PE was recently developed. PE is a complex condition with psychological, biological and social factors all at play. According to the American Urological Association, approximately one in five men between the ages of 18 and 59 report incidences of PE.

Endurance CEO Jamie Gibson said: “This represents an important milestone in the regulatory submission process in China. We now look forward to our commercial partner in China submitting the New Drug Application (NDA) to the National Medical Products Administration (NMPA) by the end of Q3 2023 with approval expected 12 months later.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Endurance also reported strong uptake of Fortacin in the EU and especially in Germany. The manufacturer released 30,000 units in February 2023, with the next 30,000 scheduled for delivery in July 2023.